Novo Nordisk escalates fight over how Lilly markets GLP-1 medicines
Eli Lilly’s push to dominate the fast‑expanding obesity and diabetes market collided this week with an aggressive legal challenge from rival Novo Nordisk, creating a dramatic backdrop for Lilly’s latest clinical milestone.
On July 23, Lilly reported strong results from two additional Phase 3 trials of retatrutide, its investigational triple‑agonist targeting GIP, GLP‑1 and glucagon receptors. The company said the drug delivered “powerful efficacy” across populations with obesity complicated by type 2 diabetes or cardiovascular disease, reinforcing its strategy to expand beyond tirzepatide‑based products such as Zepbound and Mounjaro.
In TRIUMPH‑2, adults with obesity or overweight and type 2 diabetes lost up to an average of 49.6 lbs (20.8%) at 80 weeks, alongside A1C reductions of up to 1.6%, according to Lilly’s release. In TRIUMPH‑3, adults with severe obesity and established cardiovascular disease lost up to 55.8 lbs (22.6%), while also seeing improvements in triglycerides, non‑HDL cholesterol, systolic blood pressure, waist circumference and hsCRP. Lilly said it plans to submit a Biologics License Application for retatrutide in Q1 2027.
“Across five positive Phase 3 studies, retatrutide has shown powerful efficacy,” said Kenneth Custer, Ph.D., president of Lilly Cardiometabolic Health. “We now have the clinical data package to support global submissions.”
The announcement comes as Novo Nordisk escalates a legal fight over how Lilly markets its existing GLP‑1 medicines. On July 21, Novo Nordisk filed a federal lawsuit accusing Lilly of misleading consumers through national advertising campaigns for Zepbound and Mounjaro. The complaint, filed in the U.S. District Court for the District of New Jersey, alleges Lilly’s ads rely on outdated studies that compare Lilly’s highest injectable doses against lower doses of Novo Nordisk’s Wegovy and Ozempic—omitting newer, more effective FDA‑approved options.
Novo Nordisk argues the campaigns create “the misleading impression that Lilly’s medicines are superior,” particularly by excluding Wegovy’s 7.2 mg dose, approved in March 2026, which achieved 19% weight loss (47 lbs) in the STEP UP trial. “People deserve accurate information that reflects the latest scientific evidence,” said John F. Kuckelman, Novo Nordisk’s general counsel.
The lawsuit seeks a permanent injunction requiring Lilly to withdraw the ads and launch corrective advertising. Novo Nordisk said it will move for a preliminary injunction if Lilly does not voluntarily pull the campaigns.
The clash underscores the intensifying competition in the GLP‑1 and obesity‑care market, where both companies are racing to expand indications, scale manufacturing and secure consumer mindshare. Lilly, which also maintains corporate operations in Puerto Rico as part of its global footprint, is preparing to introduce a first‑in‑class triple agonist into a market already reshaped by semaglutide and tirzepatide. Novo Nordisk, meanwhile, is defending its franchise as it rolls out higher‑dose Wegovy and continues global expansion.
With retatrutide’s Phase 3 program nearing completion and Novo Nordisk escalating its legal strategy, the rivalry between the two pharmaceutical giants is poised to sharpen as both seek to define the next era of obesity and metabolic‑health treatment.
